By H. Ugrasal. Colorado State - Pueblo. 2019.
NGI patients usually spend longer in custody than those found guilty of similar crimes and serve their sentence in the ordinary manner kamagra 50 mg. For this reason 50mg kamagra, even though there is good evidence of NGI 100mg kamagra, this avenue may not be taken so that a finite sentence will be given kamagra 100 mg. Anders Behring Brevik kamagra 100mg, Norway mass murderer 100 mg kamagra, declared insane Finding could mean treatment kamagra 50mg, not prison BY Christina Boyle NEW YORK DAILY NEWS Tuesday 50 mg kamagra, November 29 2011 , 8:52 AM Illustration . In 2011, Anders Brevik killed 8 people using a bomb in central Oslo (Norway) then drove to a youth camp on the Island of Utoeya, where he shot dead a further 69 people. He admitted his acts and stated he had done so for political purposes. This was also the initial response of the current author. However, after examining Brevic, a group of experts found that he had been psychotic at the time of the crime. They reported that he lives “in his own delusional universe, where his thoughts and actions are governed by these delusions”. Nevertheless, when the case went to court, the Judge decided that Brevic was sane, and should bear responsibility for his actions. A psychotic man attacked a female in a city in Australia. She lost a foetus, a kidney and a large piece of bowel. However, the headlines simply state that the perpetrator was found “not guilty” – this is poor journalism. Malingering Malingering is to pretend to be ill to avoid situations such as going to work or jail. It is a concern that individuals may pretend to be mentally ill and thereby avoid appropriate punishment. Malingering in forensic cases was thought to be rare (Enoch M, Ball, 2001). However, recent empirical research and clinical experience has altered our thinking, and malingering is now recognised as being much more common than previously thought - with reported prevalence rates of 30% or more (Merckelback et al 2009; Scott 2016). Unfortunately, GBMI has not significantly improved matters. This plea requires the individual to plead guilty (thus there is no need for lengthy court battles, and teams of psychiatrists giving opposing views). While the verdict suggests that treatment would then be given, this is often not the case, and there is no evidence that GBMI mitigates sentences. Diminished responsibility Diminished responsibility may be a defence to the charge of murder. If successful, the accused is found guilty of the lesser charge of manslaughter (The Homicide Act 1957, England). The important features of diminished responsibility are: 1) at the time of the crime the accused was suffering form “an abnormality of the mind”, and 2) the abnormality of mind substantially impaired mental responsibility. Many regard diminished responsibility to be a better law than either NGI or GBMI. Thus, intoxication is not sufficient for a plea of NGI, but may satisfy the requirement for diminished responsibility. Automatism For conviction of a crime there must be the performance of a prohibited physical act (actus reus). The performance of this act must have been conscious and volitional. An example would be a person strung by a bee while driving, who involuntarily dries off the road, killing a pedestrian. It has been successful with acts which have been performed while sleepwalking, during the post head injury period, and during hypoglycaemia and epileptic seizure. The future As stated in the introduction, the legal and psychiatric models are different. They have different roles and their respective practitioners have different ways of thinking. Around the world Mental Health Courts/Diversion from Custody Schemes are being established. There are differences from one jurisdiction to the next, and legal structures are not yet finalized, but the universal aim is to prevent people who have severe mental illness and commit minor offences from being incarcerated in prisons, and instead, to direct them to comprehensive treatment. Mental disorder and violence Patients suffering mental disorders are more often convicted for crimes than the general population (Walsh et al, 2002). However, this difference is not as great as some members of the public and the media appear to believe. Somewhat distorting the figures, of course, is that mentally ill offenders are more easily caught than healthy persons (Robertson, 1988). However, mental disorder was most strongly associated with arson, assault and homicidal attempts or threats. People with personality disorders, and people with IQs lower than 85 are more likely to perform sexual crimes. People with personality disorder are also more likely to commit homicide than people with other disorders. Manic illness is associated with disinhibition and there may be financial and sexual indiscretion. While people with mania may be annoying and belligerent, they rarely resort to violence. Schizophrenia is erroneously considered to be a condition frequently leading to violence. The rate of violence may be 2 to 5 times higher than among the general population, but this needs to be taken in context, that is, the rate at which members of the general population perform violence is low. Mullen (2001) places the problem in perspective, “violent behaviour in people with schizophrenia is at the same frequency as in young men”. Young men of the general population tend to grow out of violent behaviour, and some schizophrenic people do not. For people with schizophrenia, the risk is greater for family members and friends than for strangers. The risk of suicide by the individual is very much greater than the risk of any serious injury to others. The risk of violence increase about four times when there is drug or alcohol abuse, and the patient is not receiving treatment (Dr Hadrian Ball, personal communication, 2017). While people with schizophrenia can be violent as a direct response to hallucinations and delusions, this is rarely the case. Minor offences are the most common, and these are usually secondary to deterioration in personality and social functioning, and sometimes alcohol and drug use. Thought disorder and negative symptoms are common complications of the disorder; in the same way that these may prevent functioning in activities of daily life, they prevent patients planning and conducting premeditated crimes. Pathological (or morbid) jealousy is the morbid belief that the spouse is being unfaithful. This disorder may arise from chronic alcohol abuse and psychotic illness. This disorder represents a significant risk to the spouse and calls for specialist assistance. Risk Management Dangerousness refers to potential, and is a matter of opinion. The term implies an all- or-none phenomenon, a static characteristics of an individual. Dangerousness has been assessed using an “actuarial” approach, i. Age at which criminal acts were first performed and the nature of past acts are other static/actuarial facts which are correlated with the potential for future violence. Risk takes into account not only the static characteristics of the individual, but personality (e. Accordingly, modifications can be expected to reduce risk. Whether this language change from dangerousness to risk has advanced the field is a matter for discussion (Philipse et al, 2006). The prediction of violence remains an area of uncertainty (Heilbrun, 1999; Craig et al, 2006). Risk management has become an area of intense research and clinical activity in forensic psychiatry. Drug and alcohol use and compliance with treatment have emerged as major risk factors which may be modified through professional assistance. Case report 1 In 1983 human body parts were found in a sewage processing plant in Hobart, Tasmania, Australia. Subsequently, Dr Rory Jack Thompson, an American-born research oceanographer, aged 41 years, employed by the Commonwealth Scientific and Industrial Research Organization (CSIRO) was charged with the murder of his estranged American-born wife, Maureen. Dr Thompson had come to Australia in 1974 at the age of 32 years, and pursued a distinguished research career. In 1984 Dr Thompson told the court he had killed his wife to “stop her stealing” their children. Dr and Mrs Thompson were living apart at the time of the murder and their two children, aged 5 and 8 years were staying with Dr Thompson. He killed her with a club he had made from the leg of a table and dismembered her body with a meat clever and hacksaw which he had taken with him for this purpose. He said he had flushed 90% of her body pieces down the toilet and buried the remainder, including her head, in a shallow grave in nearby bush-land. He was found NGI and committed to a prison hospital under a mental health act. It was difficult for those not engaged in the court proceeding to accept this decision. He had planned and even rehearsed the murder, thus there appeared to be little evidence that the murder was the result of an irresistible impulse. He was a successful scientist, had never been treated for a psychiatric disorder and did not appear to be suffering mental disorder at the time of capture. Whether or not NGI was the most appropriate verdict, this was the verdict achieved. He was found not guilty, thus he was not in need of punishment. However, he was found insane and dangerous, which indicated he was in need of treatment. In 1990, after 7 years of incarceration Dr Thompson applied for release to the Tribunal. In 1992, Dr Thompson made another application for release. Release was again recommended and again denied by the Government of the day. He made further appeals for release in 1993 and 1994 but these were denied. In 1999 (now aged 57 years) Dr Thompson escaped from captivity but was recaptured within hours. This case illustrates some of the problems with the NGI option, in particular, the difference between the legal definition of insanity and the medical definition of mental disorder, and the difficulty securing release even when no mental disorder is (or ever was) present. The only details available on this case, on the other side of the world (to Australia), come from two brief newspaper reports. In 2001, in Houston, Texas, Andrea Yates (37 years) drowned her five children (Mary 0. Noah was afraid and Ms Yates had to chase him through the house to catch him. After each child was dead she carried the body to its bed and covered it with a sheet. Ms Yates was married to Russell, who worked with computers for NASSA. Mr Yates told that Ms Yates had suffered post-natal depression (and attempted th suicide) after the birth of their 4 child. However, she became depressed again after the birth of the 5 child, and 3 months before the murders, her father had died. Ms Yates told that at the time she killed her children, she believed she was saving them from Satan. It appears Ms Yates had been in a forensic facility for 5 years, and that she would now be transferred to a state mental hospital. And, it was anticipated that she would soon be released from the mental hospital back into the community. Although the information is limited, this appears to be a classic case of murder for which the perpetrator is NGI. It is noted that 5 years passed from apprehension to court hearing. We do not know why the process took 5 years, it may have been that Ms Yates was initially not fit to plead. In 2011 he was convicted and sentenced to 431 years jail. In 1975 (24 years of age) he was convicted of a brutal rape.
Does this change with age kamagra 100 mg, RCTs kamagra 100mg, observational Embase 1980–2008 gender kamagra 50 mg, ethnicity or presence/absence of studies Cochrane 1800–2008 proteinuria? Cinahl 1982–2008 IDEN 1 In adults 100mg kamagra, who should be tested for CKD? Systematic reviews 50 mg kamagra, Medline 1966–2008 RCTs kamagra 50mg, observational Embase 1980–2008 studies Cochrane 1800–2008 Cinahl 1982–2008 PROG 1 What constitutes a significant decline in GFR? Cinahl 1982–2008 HYPR 1 What are the most appropriate antihypertensive Systematic reviews 100 mg kamagra, Medline 1966–2008 drugs to reduce the risk of progression of CKD and RCTs Embase 1980–2008 to decrease mortality in adults with CKD? Cochrane 1800–2008 Cinahl 1982–2008 MONIT 1 In adults with CKD commencing an ACE inhibitor or Systematic reviews 50mg kamagra, Medline 1966–2008 ARB , what parameters of renal function should be RCTs , observational Embase 1980–2008 monitored and how often? RISK 1 In adults with CKD does the risk:benefit ratio of ACE Systematic reviews, Medline 1966–2008 inhibitors or ARBs change with increasing age? RCTs, observational Embase 1980–2008 studies Cochrane 1800–2008 Cinahl 1982–2008 HYPR 2 In adults with proteinuric or non-proteinuric CKD, Systematic reviews, Medline 1966–2008 does treatment with a) spironolactone alone, RCTs Embase 1980–2008 b) combinations of spironolactone and ACE inhibitors, Cochrane 1800–2008 c) combinations of spironolactone and ARBs, or Cinahl 1982–2008 d) combinations of spironolactone and ACE inhibitors and ARBs decrease mortality and reduce the risk of progression of CKD compared with placebo or other antihypertensive agents? Cinahl 1982–2008 LIPID 1 In adults with CKD and dyslipidaemia, do lipid Systematic reviews, Medline 1966–2008 lowering agents (statins, fibrates, fish oils) decrease RCTs Embase 1980–2008 cardiovascular disease risk and all cause mortality Cochrane 1800–2008 compared with placebo or each other? Cinahl 1982–2008 ANTI 1 In adults with CKD, does antiplatelet and Systematic reviews, Medline 1966–2008 anticoagulant therapy reduce cardiovascular RCTs Embase 1980–2008 morbidity and mortality compared with placebo? Cochrane 1800–2008 Cinahl 1982–2008 URIC 1 Does lowering uric acid with a) allopurinol Systematic reviews, Medline 1966–2008 b) uricosuric agents (probenecid, sulfinpyrazone) RCTs Embase 1980–2008 c) rasburicase (urate oxidase), decrease morbidity Cochrane 1800–2008 and mortality in adults with CKD and hyperuricaemia? Cinahl 1982–2008 HAEM 1 What are the adverse outcomes associated with No filters, i. Cochrane 1800–2008 Cinahl 1982–2008 BONE 1 When should serum calcium, vitamin D, phosphate Systematic reviews, Medline 1966–2008 and intact parathyroid hormone levels be routinely RCTs, observational Embase 1980–2008 measured in adults with CKD? RCTs Embase 1980–2008 Cochrane 1800–2008 Cinahl 1982–2008 EDUC 1 What information, education, and support are No filters, i. Cinahl 1982–2008 TOOLS 1 What tools for community management are needed No filters, i. This follows referral of the topic by the Department of Health. The guideline will provide recommendations for good practice that are based on the best available evidence of clinical and cost effectiveness. The statements in each NSF reflect the evidence that was used at the time the Framework was prepared. The clinical guidelines and technology appraisals published by the Institute after an NSF has been issued will have the effect of updating the Framework. The NSF for Renal Services (2005) is of particular relevance to this guideline. In an important minority of people, CKD will develop into established renal failure (ERF), necessitating treatment by dialysis and/or a kidney transplant (collectively known as renal replacement therapy, RRT) for continued survival. For a small minority of people with 4 Appendix B: Scope of the guideline significant associated comorbidity conservative management (i. Regular testing of high-risk groups (people with diabetes, hypertension, cardiovascular disease or known kidney disease, and the elderly) can give an early indication of renal damage, thus allowing the delivery of interventions at an early stage. However, the diagnosis is often delayed or missed due to a lack of specific symptoms until CKD is at an advanced stage. Factors associated with progression of CKD and with increased cardiovascular risk are similar and targeting of these risk factors may both reduce CVD in people with CKD and reduce progression of CKD to end stage renal failure. Since 2000, there has been a 22% increase in the number of people receiving RRT (an average increase of 4. Despite a wealth of literature detailing the increased hospitalisation, cost and mortality associated with late referral of people with advanced CKD to a nephrology service, late referral from both primary and secondary care is still at least as high as 30%. Late referral also precludes adequate assessment and preparation of those for whom conservative management is more appropriate. Significant costs and poor clinical outcomes are associated with the late referral of people with ERF needing RRT. Therefore, identification of people at earlier stages of CKD, appropriate management and earlier referral of those who would benefit from specialist renal services would lead to an increase in both economic and clinical effectiveness. The guideline development process: an overview for stakeholders, the public and the NHS describes how organisations can become involved in the development of a guideline. Guideline development methods: information for National Collaborating Centres and guideline developers provides advice on the technical aspects of guideline development. It defines exactly what this guideline will (and will not) examine, and what the guideline developers will consider. The scope is based on the referral from the Department of Health (see Appendix). For example this will include management of: q Hypertension and lipids, specific to CKD q Proteinuria/albuminuria q Progressive kidney disease q Renal bone disease q Acidosis q Hyperuricaemia And will incorporate q The utility of specific pharmacological interventions q Non-pharmacological interventions (such as dietary intervention, smoking cessation and exercise) 6 Appendix B: Scope of the guideline And will encompass q Monitoring of CKD q Specific conditions such as diabetes c) Timely and appropriate referral to specialist services (including criteria for referral) d) Tools for community management of CKD. The consultation period is 30th August to 27th September 2006. The guideline will cross refer where appropriate to the following NICE guidance. Information on the progress of the guideline will also be available from the website. TEST 3 What is the sensitivity and specificity of reagent strips for detecting protein and blood in urine of patients? TEST 1 What is the best test to measure renal function in routine clinical practice? TEST 2 What are the benefits in terms of accuracy and cost in measuring albumin:creatinine ratio versus protein:creatinine ratio to quantify proteinuria in adults with CKD? RISK 2 What factors are associated with progression of CKD? Which of the following are a risk factor for progression in adults with CKD? Does this change with age, gender, ethnicity or presence/absence of proteinuria? TEST 4 In adults with CKD, what is the biological and analytical variability in GFR testing and what factors (including fasting) affect it? Model 1 Non-diabetic, hypertensive adults Model 2 Non-diabetic, non-hypertensive adults (age ≥55) The model was run for different age-sex groups. Other populations, such as people with a family history of ESRD, were not explicitly considered, since their epidemiology is not as well known as in people with hypertension and diabetes. However, a sensitivity analysis was conducted to determine the cost-effectiveness of testing at different levels of prevalence. Reagent 1 strategy: GFR + Proteinuria Reagent strip test q positive strip → ACR q negative strip → No further testing 3. Reagent 2 strategy: GFR + Proteinuria Reagent strip test q positive strip → ACR q negative strip → 2nd Reagent Strip test q negative strip → positive 2nd strip → ACR q negative strip → negative 2nd strip → No further testing 4. ACR strategy: GFR + ACR In both models the no testing strategy involved natural progression of CKD. But under the testing strategies, for true positives the progression is slowed and mortality reduced due to treatment with ACE inhibitors or ARBs. Direct comparison of PCR with ACR in terms of diagnostic sensitivity and specificity was not possible since these two tests cannot meaningfully be compared against the same reference standard. However, a sensitivity analysis was conducted to find the level of sensitivity of PCR (relative to ACR) that would make PCR the more cost-effective strategy. Markov models have the advantage that they can measure outcomes, where events (such as change in CKD stage) can take place at any point over a long period of time. Such models also identify the number of events at each timepoint, which facilitates the discounting of cost and health outcomes to future values. These models have informed the development of our model. The model follows the NICE reference case,1 as follows. The costs were measured from the perspective of the National Health Services (NHS) and Personal Social Services (PSS). Health outcome was measured in terms of quality-adjusted-life-years (QALYs), where one QALY is equal to one year of full health. No testing [+] True positive True positive ACR sens_acr M [+] Reagent strip sens_strip 1 False negative M [+] Proteinuria test 1 # True positive M [+] pPUless60_HYP 1 Reagent strip True positive ACR sens_acr False negative test 2 sens_strip 1 False negative # M [+] eGFR <60 ml/min/ # 1 False negative 1. No testing [+] GFR + 2 reagent strips [+] GFR + 1 reagent strip High-risk population – [+] hypertension True positive M [+] Test positive _p61 eGFR <60 ml/min/ _p63 False positive 1. Moderate End CKD* RRT Stage 5 Stage 3–4 Death from all causes *Health state at time of diagnosis. The 100% specificity is based on the assumption that false positives will be eliminated because we recommend that a positive test is followed by a second eGFR. The 100% specificity is based on an assumption that false positives will be eliminated by a second measurement to quantify albuminuria / proteinuria. Alternative values for the sensitivity of ACR were tested by sensitivity analysis. These drugs reduce mortality and slow down the progression of disease. This was a simplification made to speed up the development of the model, but the model should still capture most of the costs and health benefits as long as eGFR and ACR are relatively specific. They receive no CKD treatment until renal replacement therapy (in the discussion below, we consider the impact of relaxing this assumption). The decision model sought to capture the following effects: q Health effects – Health gain is based on the prescription of high dose ACE inhibitor/ARB therapy on diagnosis of CKD. These are known to reduce mortality and slow down the progression of disease. A range of cost estimates obtained from NHS laboratories was used in a two-way sensitivity analysis. So for example: q In people with hypertension aged 60, the prevalence of cases is 19. For the purposes of the model, the GFR estimation is assumed to be 100% sensitive and specific. The sensitivity and specificity of ACR was also assumed to be 100% in the base case analysis. For both GFR and ACR, a second test was costed following an initial positive test. The sensitivity (92%) and specificity (62%) of the reagent strip test were averages from the two studies83,84 in the clinical review that measured sensitivity and specificity with a cut-off of 0. For this we turned to the Cochrane review on ACE inhibitor treatment in diabetic nephropathy (N=3215). These relative risk reductions were assumed to apply to true positive patients in both models (both with and without hypertension). It was assumed that a proportion of patients would be put on ARBs because they could not tolerate ACE inhibitors. For this proportion we used 6% (the proportion of patients experiencing cough after ACEI therapy). Mortality associated with adverse events is incorporated in the estimates of overall mortality. Morbidity due to adverse events is difficult to quantify; the trial data do not suggest that there is major morbidity. We tentatively estimated progression from ESRD to RRT as follows: q incidence of RRT in England per million population = 104 per million (UK Renal Registry 2006)9 q population of England = 55 million q new cases of RRT in England per year = 5720 (= a*b) q prevalence of ESRD = 0. We estimate the annual progression probability from ESRD to RRT to be c/e = 5720/38,500 = 0. The costs of testing incorporated initial GFR estimation, reagent strip testing and/or ACR estimation and GP practice nurse time costs (see Table C. It was assumed that following a GFR test result, high-risk individuals would be requested to visit the GP surgery to provide a urine sample for urinalysis. They may be attended to by either the practice nurse or health care assistant. Therefore a single visit to a GP practice nurse is accounted for in testing strategies 3 and 4. In strategy 2, a second visit is costed if the first urinalysis is negative. Following the review and recording of results, action may involve no further assessment or may contribute to a follow-up appointment with GP or practice nurse or a referral to specialist care. These drugs are the most widely prescribed for hypertension. The drug costs are different for those with neither diabetes nor hypertension, inasmuch as there are no drug costs for hypertension other than ACE inhibitor/ARB therapy for the true positives. The use of services was divided according to resources required on diagnosis of CKD as well as the annual use after diagnosis. The numbers of visits per year, by CKD stage367 were multiplied by the NHS reference cost for a nephrology outpatient visit. Using reference costs for general renal disorder admissions that were differentiated by age, the cost of inpatient admissions according to age and stage were calculated. The cost of RRT was weighted according to these proportions. The cost of a renal transplant used in the model was £20,000 in the first year and £6500 per year for the years following transplantation (Palmer et al. These costs include hospitalisation, drugs and treatment of complications. The Australian model used utility-based quality of life scores derived from data collected in the Australian Diabetes and Lifestyle study (Ausdiab). This study assessed the health-related quality of life (HRQOL) of 135 haemodialysis and peritoneal dialysis patients. The number of years in each stage of CKD, on RRT and QALYs resulting from each strategy is presented in Table C.
Brain Cogn magnetic resonance imaging of the basal ganglia 50 mg kamagra. Case study: acute response inhibition abnormalities in pediatric obsessive-com- basal ganglia enlargement and obsessive-compulsive symptoms pulsive disorder 100 mg kamagra. MRI assessment of dysfunction in fronto-striatal circuits kamagra 50 mg. J Psychiatry Neurosci children with obsessive-compulsive disorder or tics associated 1997;22:29–38 kamagra 100 mg. Go-no go learning after frontal lobe lesions in hu- in tic kamagra 100mg, obsessive-compulsive 50mg kamagra, and attention deficit/hyperactivity mans 100mg kamagra. Antibodies reacting tion after bilateral frontal lobe ablation: patient EVR kamagra 50mg. Neurology with cytoplasm of subthalamic and caudate nuclei neurons in 1985;35:1731–1741 . Obsessive-conpulsive disorder: diagnosis and treatment , 2nd mune neuropsychiatric disorders. The amygdala: neurobiological aspects of emotion, models of obsessive-compulsive disorders. Anterior paralimbic 'prefrontal' and 'limbic' functions. In: Uylings HBM, mediation of procaine-induced emotional and psychosensory VanEden CG, DeBruin JPC, et al, eds. Brain mediation of obses- vation detected with echo-planar functional magnetic resonance sive-compulsive disorder symptoms: evidence from functional imaging. Neurobiology of fear responses: the role of the amyg- Semin Clin Neuropsychiatry 1996;1:32–47. Anti-anxiety action of diazepam ropsychiatric disorders. J Neuropsychiatry Clin Neurosci 1994;6: after intra-amygdaloid application in the rat. Evidence that the amygdala is behaviors following orbital frontal lesions in rhesus monkeys. The prefrontal cortex: anatomy, physiology and neuro- ation of aversive behavior in the mouse. Br J Pharmacol 1989; psychology of the frontal lobe, second ed. Arch Gen Psychiatry 1992;49: social interaction test, but not in the elevated plus-maze. Positron emission tomography studies of cerebral 60. Obsessive-compulsive disorder: is it basal glucose metabolism in obsessive-compulsive disorder. Anatomy and function of the orbital frontal Psychiatric Press, 1989:327–347. I: Anatomy, neurocircuitry, and obsessive-compulsive 61. II: Function and relevance to obsessive-compulsive dis- 63. Evaluation of marble- and positron emission tomography. Arch Gen Psychiatry 1994; burying behavior: induced alteration of monoamine metabolism 51:62–70. Compulsive thalamic volume in obsessive-compulsive disorder. Arch Gen Psychiatry self-stimulation: a case with metabolic, electrophysiologic and 1995;52:393–398. Neuroimaging and in women with obsessive-compulsive disorder and trichotillo- frontal-subcortical circuitry in obsessive-compulsive disorder. Neuroimaging research and the neurobiology of ob- striatal measurement of treatment-naive pediatric obsessive- sessive-compulsive disorder: where do we go from here? FDG-PET predictors model of obsessive-compulsive disorder. Biol Psychiatry 1998; of response to behavioral therapy versus pharmacotherapy in 43:623–640. In Oldham JM, Riba MB, Tas- phy and neuropsychological test measures in adolescents with man A, eds. Washington, DC: American Psychiatric Press, obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 1997;21: 91. Prog Neuropsychopharmacol Biol Psychiatry 1997;21: and cognitive impairment in chronic schizophrenia. Abnormalities of the signal intensity in treatment naive pediatric obsessive-compul- left temporal lobe and thought disorder in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 1999; quantitative magnetic resonance imaging study. MRI volumetric mea- nucleus size in obsessive-compulsive disorder: detection with surement of amygdala and hippocampus in temporal lobe epi- magnetic resonance imaging. The neuromorphometry of affective nucleus in obsessive-compulsive disorder assessed by quantita- disorders. Neuroanatomical lamic volumes of pediatric obsessive-compulsive disorder pa- abnormalities in obsessive-compulsive disorder determined with tients taking paroxetine. Arch Gen Psychiatry 2000;57(5): quantitative x-ray computed tomography. Computed tomography nuclei volumes of first-episode schizophrenic patients taking and neurological soft signs in obsessive-compulsive disorder. A short echo 1H compulsive disorder patients taking paroxetine. J Am Acad Child spectroscopy and volumetric MRI study of the corpus striatum Adolesc Psychiatry 2000;39(9):1096–1103. Event-related functional struction techniques from magnetic resonance images. Spatiotemporal imaging of an adolescent with obsessive-compulsive disorder and atypical human brain activity using functional MRI constrained magnet- anorexia nervosa. Generalized dystonia and obsessive-compulsive Acad Sci USA 1998;95:8945–8950. Bicaudate ratio as a nance signal changes in the putamen. J Nerv Ment Dis 1995; measure of caudate volume on MR images. Retrocallosal white bodies: tics and obsessive-compulsive symptoms. J Dev Behav matter abnormalities in patients with obsessive-compulsive dis- Pediatr 1994;15:421–425. Cerebral structural abnor- neuropsychiatric disorders associated with streptococcal infec- malities in obsessive-compulsive disorder: a quantitative mor- tions: clinical description of the first 50 cases. Am J Psychiatry phometric magnetic resonance imaging study. Age and sex effects for affect ties of frontal neocortex in obsessive-compulsive disorder. Computerized volume mea- Arch Gen Psychiatry 1999;56:913–919. Ipsilateral subcortical on discrimination learning and performance. In: Delafresnaye atrophy associated with temporal lobectomy. Visual discrimination learning after selective volumetry. Developmental progression in human infants and and after cognitive behavioral therapy. Biol Psychiatry 2000;48: infant monkeys, and the neural bases of, inhibitory control of 294–300. New York: Academy of Science pletes serotonin from the developing cortex and alters thalamo- Press, 1990:267–317. Neuroimaging and neuropsychology of Basic Books, 1996. Perseverative interference in monkeys ison with rates in unipolar depression and normal controls. Arch following selective lesions of the inferior prefrontal convexity. An assessment of aphasia and related bolic rates in non-depressed patients with obsessive-compulsive disorders. Functional heterogeneity of the prefrontal cor- 138. Behav Neural Biol 1979;25: metabolic rates in obsessive-compulsive disorder. Br J Psychiatry 1994;164: J Neurophysiol 1989;61:331–349. Functional magnetic dorsolateral prefrontal cortex of the rhesus monkey. Exp Neurol resonance imaging of symptom provocation in obsessive-com- 1970;27:291–304. J Neuropathol Exp Neurol 1985;44: metabolism in anxiety disorders studied with positron emission 578–591. New York: Liss, 1986: regional cerebral perfusion abnormalities in obsessive-compul- 47–73. A small step for the cell, a giant leap for mankind: a 144. Elevated medial- hypothesis of neocortical expansion during evolution. Trends frontal cerebral blood flow in obsessive-compulsive patients: a Neurosci 1995;18:383–388. Regional develop- anatomy of CCK4-induced anxiety in normal healthy volun- ment of the brain in early life. Arch Neurol roanatomy of anxiety: a study of three disorders using positron Psychiatry 1937;38:725–743. Neuroanatomical to paroxetine treatment in obsessive-compulsive disorder. Systematic changes 1644 Neuropsychopharmacology: The Fifth Generation of Progress in cerebral glucose metabolic rate after successful behavior modi- 166. Changes in platelet fication treatment of obsessive-compulsive disorder. Arch Gen markers of obsessive-compulsive patients during a double-blind Psychiatry 1996;53:109–113. Serotonin uptake and imipra- tients treated with clomipramine. Arch Gen Psychiatry 1990;47: mine binding in the blood platelets of obsessive-compulsive 840–848. Peripheral markers in childhood-onset obsessive-compulsive disorder: revisualiza- of serotonin and dopamine function in obsessive-compulsive tion during pharmacotherapy. Regional mine binding and serotonin uptake in platelets of eight adoles- 133Xenon cerebral blood flow and cerebral 99mTc-HMPAO up- cent and ten adult obsessive-compulsive patients. J Am Acad Child Adolesc Psy- ture review of a compound prominent in 1H-NMR spectro- chiatry 1996;35:1647. Obsessive-compulsive epilepticus: 1H magnetic resonance spectroscopic imaging. Biol Psychiatry Cereb Blood Flow Metab 1994;14:373–382. Platelet 3H-imipra- spectroscopy in obsessive-compulsive disorder: evidence for neu- mine binding sites in obsessive-compulsive behavior. Biol Psy- ronal loss in the cingulate gyrus and the right striatum. Proton spectro- ing and serotonin uptake in obsessive-compulsive patients. Acta scopic imaging of the thalamus in treatment-naive pediatric ob- Psychiatr Scand 1991;84:29. Functions of inotropic and metabotropic ment of obsessive-compulsive disorder. Chemical anatomy of primate nal fluid biogenic amines in obsessive-compulsive disorder, basal ganglia. In vivo evidence for an inhibi- macol Bull 1982;18:13. Neurobiology of obsessive-compulsive tory glutamatergic control of serotonin release in the cat caudate disorder. Increased cerebral blood projection: from synaptic plasticity to dysfunction of the basal flow during mCPP exacerbation of obsessive-compulsive disor- ganglia. Serotonin-releasing effects of substi- release in the guinea pig orbito-frontal cortex by selective seroto- tuted piperazine in vitro. Neuropsychopharmacology 1995;13: responses associated with 5-HT1c receptors. Effects of ritanserin on measurements of cerebral glutamine synthesis as evidence for the behavioral, neuroendocrine, and cardiovascular responses to glutamate-glutamine cycling. Proc Natl Acad Sci USA 1997; meta-chlorophenylpiperazine in healthy human subjects.
8 of 10 - Review by H. Ugrasal
Votes: 165 votes
Total customer reviews: 165